Serum hepatitis B surface antigen is correlated with intrahepatic total HBV DNA and cccDNA in treatment-naïve patients with chronic hepatitis B but not in patients with HBV related hepatocellular carcinoma

Journal of Medical Virology

Volumn 85, Issue 2, 2013, Pages 219-227

  Wang, Meirong ^a   Qiu, Ning ^a   Lu, Shichun ^b   Xiu, Dianrong ^c   Yu, Jianguo ^d   Wang, Xing tai ^e   Lu, Fengmin ^a   Li, Tong ^a   Liu, Xueen ^a   Zhuang, Hui ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY THIRD HOSPITAL   (China)

^d No 88 Hospital of People's Liberation Army   (China)

^e MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

Chronic hepatitis B; Covalently closed circular DNA; Hepatitis B surface antigen; Hepatitis B virus; Hepatocellular carcinoma; Total HBV DNA

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; COVALENTLY CLOSED CIRCULAR DNA; DEOXYRIBONUCLEASE; HEMOGLOBIN BETA CHAIN; HEPATITIS B SURFACE ANTIGEN; UNCLASSIFIED DRUG; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HOUSEKEEPING GENE; HUMAN; LIVER CELL CARCINOMA; LIVER PARENCHYMA; MALE; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER NEOPLASMS; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; STATISTICS AS TOPIC; VIRAL LOAD; YOUNG ADULT;

HEPATITIS B VIRUS;

EID: 84871076917     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23461     Document Type: Article

References (39)

1. Abdelhamed AM, Kelley CM, Miller TG, Furman PA, Isom HC. 2002. Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatment. J Virol 76:8148-8160.
2. Addison WR, Walters KA, Wong WW, Wilson JS, Madej D, Jewell LD, Tyrrell DL. 2002. Half-life of the duck hepatitis B Virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol 76:6356-6363.
3. Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Sezaki H, Kobayashi M, Kumada H. 2006. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 119:71.e9-71.e16.
4. Bourne EJ, Dienstag JL, Lopez VA, Sander TJ, Longlet JM, Hall JG, Kwiatkowski RW, Wright T, Lai CL, Condreay LD. 2007. Quantitative analysis of HBV cccDNA from clinical specimens: Correlation with clinical and virological response during antiviral therapy. J Viral Hepat 14:55-63.
5. Brechot C. 2004. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: Old and new paradigms. Gastroenterol 127:S56-S61.
6. Brunetto MR. 2010. A new role for an old marker, HBsAg. J Hepatol 52:475-477.
7. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P. 2009. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 49:1141-1150.
8. Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, Wong GL, Sung JJ. 2007. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 5:1462-1468.
9. Chang TT, Gish RG, de Man RA, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D, BEHoLD AI463022 Study Group. 2006. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354:1001-1010.
10. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH, REVEAL-HBV Study Group. 2006a. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. J Amer Med Assoc 295:65-73.
11. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. 2006b. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Amer J Gastroenterol 101:1797-1803.
12. Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, Ferrari TC, Guettier C, Dussaix E, Castaing D, Brechot C, Samuel D. 2008. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterol 134:1890-1899.
13. Ganem D, Prince AM. 2004. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 350:1118-1129.
14. Guner R, Karahocagil M, Buyukberber M, Kandemir O, Ural O, Usluer G, Inan D, Koksal I, Baykam N, Hizel K, Yamazhan T, Esen S, Tasyaran M. 2011. Correlation between intrahepatic hepatitis B virus cccDNA levels and other activity markers in patients with HBeAg-negative chronic hepatitis B infection. Eur J Gastroenterol Hepatol 23:1185-1191.
15. Kim BY, Suh KS, Lee JG, Woo SR, Park IC, Park SH, Han CJ, Kim SB, Jeong SH, Yeom YI, Yang SJ, Kim CM, Cho SJ, Yoo YD, Cho MH, Jang JJ, Choi DW, Lee KH. 2012. Integrated analysis of prognostic gene expression profiles from hepatitis B virus-positive hepatocellular carcinoma and adjacent liver tissue. Ann Surg Oncol 19:328-338.
16. Laras A, Koskinas J, Dimou E, Kostamena A, Hadziyannis SJ. 2006. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 44:694-702.
17. Lee WM. 1997. Hepatitis B virus infection. N Engl J Med 337:1733-1745.
18. Li T, Ren WH, Xun SF, Zhu YH, Han GQ, Shi J. 2008a. Clinical and pathological relationship between quantity of hepatitis B virus covalently closed circular DNA and hepatocellular carcinoma. Linchuang Jianyan Zazhi 26:188-189; (in Chinese).
19. Li WP, Li T, Yan L, Liu BM, Zhuang H. 2008b. Construction of a 1.2-genome length genotype C HBV construct and study on its expression and replication in HepG2 cells. Chinese Hepatol 13:211-215; (in Chinese).
20. Lin LY, Wong VW, Zhou HJ, Chan HY, Gui HL, Guo SM, Wang H, Huang L, Bao SS, Xie Q, Chan HL. 2010. Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients. J Med Virol 82:1494-1500.
21. Mendy ME, Welzel T, Lesi OA, Hainaut P, Hall AJ, Kuniholm MH, McConkey S, Goedert JJ, Kaye S, Rowland-Jones S. 2010. Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J Viral Hepat 17:115-122.
22. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. 1997. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 71:9392-9399.
23. Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, Locarnini S. 1995. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 69:3350-3357.
24. Pan AH, Huang GY, Chen J, He YL. 2009. Relationship between hepatitis B virus covalently closed circular DNA and HBx protein expression in hepatocellular carcinoma and its significance. Shijie Huaren Xiaohua Zazhi 17:712-715; (in Chinese).
25. Perrillo R. 2009. Benefits and risks of interferon therapy for hepatitis B. Hepatology 49:S103-S111.
26. Pollicino T, Squadrito G, Cerenzir G, Cacciola I, Raffa G, Craxi A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G. 2004. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterol 126:102-110.
27. Singh M, Dicaire A, Wakil AE, Luscombe C, Sacks SL. 2004. Quantitation of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) in the liver of HBV infected patients by LightCycler real-time PCR. J Virol Methods 118:159-167.
28. Thompson AJV, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, Slavin J, Bowden S, Gane EJ, Abbott W, Lau GK, Lewin SR, Visvanathan K, Desmond PV, Locarnini SA. 2010. Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 51:1933-1944.
29. Tong MJ, Nguyen MO, Tong LT, Blatt LM. 2009. Development of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen. Clin Gastroenterol Hepatol 7:889-893.
30. Turin F, Borel C, Benchaib M, Kay A, Jamard C, Guguen-Guillouzo C, Trépo C, Hantz O. 1996. n-Butyrate, a cell cycle blocker inhibits early amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of duck hepatocytes. J Virol 70:2691-2696.
31. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE, IV., Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F. 2004. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterol 126:1750-1758.
32. Wong DK, Yuen MF, Yuan H, Sum SS, Hui CK, Hall J, Lai CL. 2004. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 40:727-737.
33. Wong DK, Yuen MF, Poon RT, Yuen JC, Fung J, Lai CL. 2006. Quantification of hepatitis B virus covalently closed circular DNA in patient in hepatocellular carcinoma. J Hepatol 45:553-559.
34. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J. 2006. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 44:675-684.
35. Yu MW, Chiu YH, Yang SY, Santella RM, Chern HD, Liaw YF, Chen CJ. 1999. Ctyochrome P450 1A1 genetic polymorphisms and risk of hepatocellular carcinoma among chronic hepatitis B carriers. Br J Cancer 80:598-603.
36. Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, Siu CW, Sander TJ, Bourne EJ, Hall JG, Condreay LD, Lai CL. 2004. HBsAg seroclearance in chronic hepatitis B in the chinese: Virological, histological, and clinical aspects. Hepatology 39:1694-1701.
37. Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, Lau K, Yuen JC, Lai CL. 2008. HBsAg seroclearance in chronic hepatitis B in Asian patients: Replicative level and risk of hepatocellular carcinoma. Gastroenterol 135:1192-1199.
38. Zhang T, Han T, Gao YT, Chen H, Du Z, Wang YJ. 2007. Detection of hepatitis B Virus cccDNA in liver tissues of patients with hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi 15:232-233; (in Chinese).
39. Zhang YY, Zhang BH, Theele D, Litwin S, Toll E, Summers J. 2003. Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus infected liver. Proc Natl Acad Sci U S A 100:12372-12377.